Market Cap | 38.24M | P/E | - | EPS this Y | 39.10% | Ern Qtrly Grth | - |
Income | -69.67M | Forward P/E | -0.82 | EPS next Y | -5.70% | 50D Avg Chg | -3.00% |
Sales | - | PEG | -0.14 | EPS past 5Y | - | 200D Avg Chg | -17.00% |
Dividend | N/A | Price/Book | 0.22 | EPS next 5Y | 5.20% | 52W High Chg | -72.00% |
Recommedations | 2.50 | Quick Ratio | 8.35 | Shares Outstanding | 41.50M | 52W Low Chg | 30.00% |
Insider Own | 6.71% | ROA | -24.61% | Shares Float | 21.21M | Beta | 1.09 |
Inst Own | 50.89% | ROE | -41.05% | Shares Shorted/Prior | 37.83K/68.90K | Price | 0.97 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 110,488 | Target Price | 2.83 |
Oper. Margin | - | Earnings Date | May 8 | Volume | 33,280 | Change | -4.66% |
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Chardan Capital | Buy | Apr 5, 24 |
Piper Sandler | Neutral | Apr 5, 24 |
B of A Securities | Underperform | Dec 14, 23 |
Chardan Capital | Buy | Aug 7, 23 |
Chardan Capital | Buy | May 11, 23 |
Chardan Capital | Buy | Dec 7, 22 |
Piper Sandler | Overweight | Dec 7, 22 |
JP Morgan | Underweight | Apr 26, 21 |
B of A Securities | Buy | Apr 26, 21 |